Heuvel2020 - An overview of the first 5 years of the ENIGMA obsessive-compulsive disorder working group, The power of worldwide collaboration

  • Type:#article
  • Year read:#read2022
  • Subject: OCD
  • Bibtex: @heuvel2020
  • Bibliography: Heuvel, O. A., Boedhoe, P. S. W., Bertolin, S., Bruin, W. B., Francks, C., Ivanov, I., Jahanshad, N., Kong, X., Kwon, J. S., O’Neill, J., Paus, T., Patel, Y., Piras, F., Schmaal, L., Soriano‐Mas, C., Spalletta, G., Wingen, G. A., Yun, J., Vriend, C., … Yamada, K. (2020). An overview of the first 5 years of the ENIGMA obsessive–compulsive disorder working group: The power of worldwide collaboration. Human Brain Mapping, 43(1), 23–36. https://doi.org/10.1002/hbm.24972

Example citation

Key takeaways

  • The OCD group in ENIGMA currently has 47 samples from 34 institutes in 15 countries on 5 continents, total n = 2323
  • Smaller hippocampus (d = -0.13), larger pallidum (d = 0.16). Medicated adult OCD patients have lower cortical thickness (d’s between -0.10 and -0.26)
  • Disease chronicity has an impact on multiple brain measures, providing additional incentive to provide treatment.

One example is the unexpected, but robust finding that medication status and disease chronicity both have a marked impact on all brain measures analyzed to date. This has two direct implications: First, it emphasizes the importance of establishing longitudinal studies to examine the beneficial and potential harmful effects of medication on the developing brain and; second, the fact that disease chronicity is related to marked morphological alterations of the brain might provide additional incentive to invest in the implementation of state-of-the-art interventions (e.g., exposure treatment requires significant scale up across the globe) and the development of innovative treatments for those who do not respond to first line interventions.